CMK389 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
84サルコイドーシス5

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000381-11-GB
(EUCTR)
09/11/202016/06/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czech Republic;Poland;Denmark;Germany;United Kingdom
2EUCTR2018-000381-11-PL
(EUCTR)
06/10/202023/07/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom
3NCT04064242
(ClinicalTrials.gov)
September 23, 202020/8/2019Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisPulmonary SarcoidosisDrug: CMK389;Drug: PlaceboNovartis PharmaceuticalsNULLRecruiting18 Years75 YearsAll66Phase 2United States;Czechia;Denmark;Germany;Poland;United Kingdom
4EUCTR2018-000381-11-DK
(EUCTR)
24/08/202030/06/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom
5EUCTR2018-000381-11-DE
(EUCTR)
16/06/202031/01/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom